Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.7,34760,DB00146,Calcidiol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.8,34761,DB00146,Calcidiol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.8,34762,DB00146,Calcidiol
,2709678,production,"25(OH)D treatment did not affect production rates in normal dogs and in animals with moderate renal failure (with normal basal values of 1,25(OH)2D), but significantly increased 1,25(OH)2D production from 0.13 +/- 0.01 to 0.25 +/- 0.04 micrograms/day (P less than 0.05) in dogs with severe renal insufficiency.",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),,0,34763,DB00146,Calcidiol
,21477267,T(max),The median for digoxin T(max) was 0.75 h before and after vitamin D3 ingestion.,Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin--a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477267/),h,0.75,41061,DB00146,Calcidiol
,31518424,rate to reach steady state,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,7,44141,DB00146,Calcidiol
,31518424,time to reach,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,7,44142,DB00146,Calcidiol
,31518424,time to reach,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,10,44143,DB00146,Calcidiol
,31518424,time to reach,"The rate to reach steady state was similar in all groups, but the time to reach 25(OH)D concentrations of 75 nmol/L was faster in the higher-dosed 25(OH)D3 groups than in the D3 group (7 and 10 d compared with 40 d, P < 0.0001 and P < 0.0001 for 15 and 20 µg/d).",Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518424/),d,40,44144,DB00146,Calcidiol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],25.8,51628,DB00146,Calcidiol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],20.2,51629,DB00146,Calcidiol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],20.2,51630,DB00146,Calcidiol
,2405696,apparent volume of distribution,"Similarly, the apparent volume of distribution of 1,25(OH)2D in the pregnant rats (15 +/- 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 +/- 2.1 ml).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),ml,15,51631,DB00146,Calcidiol
,2405696,apparent volume of distribution,"Similarly, the apparent volume of distribution of 1,25(OH)2D in the pregnant rats (15 +/- 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 +/- 2.1 ml).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),ml,18,51632,DB00146,Calcidiol
,2405696,Production rates,"Production rates of.1,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[pg] / [min],2.83,51633,DB00146,Calcidiol
,2405696,Production rates,"Production rates of.1,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[pg] / [min],1.55,51634,DB00146,Calcidiol
,21632810,D₂,"From a common baseline D₂ (1.5 ± 1.6 nmol/liter, P =0.34) the groups diverged (time × group interaction P = 0.04), peaking at 70 ± 34 nmol/liter at 6 h in controls compared with 43 ± 28 nmol/liter in AN subjects (P = 0.008).",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],1.5,64360,DB00146,Calcidiol
,21632810,D₂,"From a common baseline D₂ (1.5 ± 1.6 nmol/liter, P =0.34) the groups diverged (time × group interaction P = 0.04), peaking at 70 ± 34 nmol/liter at 6 h in controls compared with 43 ± 28 nmol/liter in AN subjects (P = 0.008).",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],70,64361,DB00146,Calcidiol
,21632810,D₂,"From a common baseline D₂ (1.5 ± 1.6 nmol/liter, P =0.34) the groups diverged (time × group interaction P = 0.04), peaking at 70 ± 34 nmol/liter at 6 h in controls compared with 43 ± 28 nmol/liter in AN subjects (P = 0.008).",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],43,64362,DB00146,Calcidiol
,21632810,D₃,"Baseline D₃ was higher in AN subjects (12.1 ± 9.6 vs. 3.1 ± 2.3 nmol/liter, P < 0.001) and remained higher throughout.",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],12.1,64363,DB00146,Calcidiol
,21632810,D₃,"Baseline D₃ was higher in AN subjects (12.1 ± 9.6 vs. 3.1 ± 2.3 nmol/liter, P < 0.001) and remained higher throughout.",Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632810/),[nM] / [l],3.1,64364,DB00146,Calcidiol
<,21667092,Ca/Cr clearance ratio,"In the group of patients with Ca/Cr clearance ratio <0.01, seven patients had hypercalcemia, and four patients had hypercalcemia and elevated iPTH.",Impaired regulation of calcium excretion in kidney transplant recipients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21667092/),,0.01,66451,DB00146,Calcidiol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,13.9,68088,DB00146,Calcidiol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.1,68089,DB00146,Calcidiol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,12.8,68090,DB00146,Calcidiol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,14.7,68091,DB00146,Calcidiol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.1,68092,DB00146,Calcidiol
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.6,68093,DB00146,Calcidiol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.03,68094,DB00146,Calcidiol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.04,68095,DB00146,Calcidiol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.04,68096,DB00146,Calcidiol
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.06,68097,DB00146,Calcidiol
,18326608,concentration maximum,Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 27.1 +/- 7.7 ng/mL to a concentration maximum of 42.0 +/- 9.1 ng/mL.,"Pharmacokinetics of a single, large dose of cholecalciferol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18326608/),[ng] / [ml],42.0,69056,DB00146,Calcidiol
,18326608,highest achieved concentration,The highest achieved concentration in any subject was 64.2 ng/mL.,"Pharmacokinetics of a single, large dose of cholecalciferol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18326608/),[ng] / [ml],64.2,69057,DB00146,Calcidiol
,3667442,half-life,Physiological half-life of the tritiated 2500 HD3 in wethers exposed to ultraviolet irradiation was 388 +/- 26.4 h (means +/- SE); in the control it was 393 +/- 29.6 h (P greater than .05).,Kinetics of intravenously administered 25-hydroxyvitamin D3 in sheep and the effect of exposure to ultraviolet radiation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667442/),h,388,78066,DB00146,Calcidiol
,3667442,half-life,Physiological half-life of the tritiated 2500 HD3 in wethers exposed to ultraviolet irradiation was 388 +/- 26.4 h (means +/- SE); in the control it was 393 +/- 29.6 h (P greater than .05).,Kinetics of intravenously administered 25-hydroxyvitamin D3 in sheep and the effect of exposure to ultraviolet radiation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667442/),h,393,78067,DB00146,Calcidiol
,33115916,clearances,"Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).",Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115916/),[ml] / [d],360,90196,DB00146,Calcidiol
,33115916,clearances,"Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).",Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115916/),[ml] / [d],313,90197,DB00146,Calcidiol
,33115916,clearances,"Mean 25(OH)D clearances were 360 ml/d, 313 ml/d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).",Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33115916/),[ml] / [d],263,90198,DB00146,Calcidiol
,8399781,terminal serum half-time (t 1/2),"In the healthy subjects without calcium supplementation, the basal (24R)-hydroxycalcidiol concentration (Cb) in serum was 2.4 +/- 0.8 nmol/l (mean +/- SD, n = 5), the terminal serum half-time (t 1/2) 7.2 +/- 1.4 days, the production rate 0.05 +/- 0.01 nmol/kg.day, and the production rate/[calcidiol] ratio (1.5 +/- 0.4 x 10(-3) l/kg.day).",Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399781/),d,7.2,101529,DB00146,Calcidiol
,8399781,production rate,"In the healthy subjects without calcium supplementation, the basal (24R)-hydroxycalcidiol concentration (Cb) in serum was 2.4 +/- 0.8 nmol/l (mean +/- SD, n = 5), the terminal serum half-time (t 1/2) 7.2 +/- 1.4 days, the production rate 0.05 +/- 0.01 nmol/kg.day, and the production rate/[calcidiol] ratio (1.5 +/- 0.4 x 10(-3) l/kg.day).",Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399781/),[nM] / [d·kg],0.05,101530,DB00146,Calcidiol
,8399781,production rate/[calcidiol] ratio,"In the healthy subjects without calcium supplementation, the basal (24R)-hydroxycalcidiol concentration (Cb) in serum was 2.4 +/- 0.8 nmol/l (mean +/- SD, n = 5), the terminal serum half-time (t 1/2) 7.2 +/- 1.4 days, the production rate 0.05 +/- 0.01 nmol/kg.day, and the production rate/[calcidiol] ratio (1.5 +/- 0.4 x 10(-3) l/kg.day).",Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399781/),[l] / [d·kg],1.5,101531,DB00146,Calcidiol
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,20,132032,DB00146,Calcidiol
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,35.2,132033,DB00146,Calcidiol
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,51.3,132034,DB00146,Calcidiol
,3006671,half-lives,Pharmacokinetic analysis of the changes in D3 concentration in rats showed that the disposition kinetics of D3 was explained by a two-compartment model with half-lives of 13.8 and 7.7 days.,Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),d,13.8,152948,DB00146,Calcidiol
,3006671,half-lives,Pharmacokinetic analysis of the changes in D3 concentration in rats showed that the disposition kinetics of D3 was explained by a two-compartment model with half-lives of 13.8 and 7.7 days.,Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),d,7.7,152949,DB00146,Calcidiol
,3006671,volume of distribution,"The volume of distribution of the more-slowly-turning-over compartment was 500 ml, which presumably reflects the large amounts of D3 that can accumulate in adipose tissue.",Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),ml,500,152950,DB00146,Calcidiol
,3006671,t1/2,"Adipose-tissue D3 is available for use by the rat, the t1/2 being 12.0 days.",Interrelationships in rats of tissue pools of cholecalciferol and 25-hydroxycholecalciferol formed in u.v. light. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006671/),d,12.0,152951,DB00146,Calcidiol
,15956292,bioavaila,"A second study was conducted to determine whether the bioavailability of vitamin D2 in cheese (delivering 5880 IU of vitamin D2/56.7-g serving) and water (delivering 32,750 IU/250 mL) is similar and whether absorption differs between younger and older adults.",Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956292/),,58,160553,DB00146,Calcidiol
,15956292,bioavaila,"A second study was conducted to determine whether the bioavailability of vitamin D2 in cheese (delivering 5880 IU of vitamin D2/56.7-g serving) and water (delivering 32,750 IU/250 mL) is similar and whether absorption differs between younger and older adults.",Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956292/),,32,160554,DB00146,Calcidiol
,15531486,Area under the curve (AUC),Area under the curve (AUC) to d 28 was 60.2 ng.d/ml (150.5 nmol.d/liter) for vitamin D(2) and 204.7 (511.8) for vitamin D(3) (P < 0.002).,Vitamin D2 is much less effective than vitamin D3 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531486/),[d·ng] / [ml],60.2,183906,DB00146,Calcidiol
,15531486,Area under the curve (AUC),Area under the curve (AUC) to d 28 was 60.2 ng.d/ml (150.5 nmol.d/liter) for vitamin D(2) and 204.7 (511.8) for vitamin D(3) (P < 0.002).,Vitamin D2 is much less effective than vitamin D3 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531486/),[d·nM] / [l],150.5,183907,DB00146,Calcidiol
,15531486,Area under the curve (AUC),Area under the curve (AUC) to d 28 was 60.2 ng.d/ml (150.5 nmol.d/liter) for vitamin D(2) and 204.7 (511.8) for vitamin D(3) (P < 0.002).,Vitamin D2 is much less effective than vitamin D3 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531486/),,204.7,183908,DB00146,Calcidiol
,34008842,AUC,The PKS of 900 µg vitamin D3 revealed that malabsorptive patients had 64% lower AUC than healthy participants (1177 ± 425 vs. 3258 ± 496 ng · h/mL; P < 0.05).,"A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],1177,188321,DB00146,Calcidiol
,34008842,AUC,The PKS of 900 µg vitamin D3 revealed that malabsorptive patients had 64% lower AUC than healthy participants (1177 ± 425 vs. 3258 ± 496 ng · h/mL; P < 0.05).,"A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],3258,188322,DB00146,Calcidiol
,34008842,AUC,"The PKS of 900 µg vitamin D3 showed that the higher BMI group had 53% lower AUC than the lower BMI group (2089 ± 490 vs. 4427 ± 313 ng · h/mL; P < 0.05), whereas AUCs of 900 µg 25(OH)D3 were not significantly different between the 2 groups (P = 0.500).","A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],2089,188323,DB00146,Calcidiol
,34008842,AUC,"The PKS of 900 µg vitamin D3 showed that the higher BMI group had 53% lower AUC than the lower BMI group (2089 ± 490 vs. 4427 ± 313 ng · h/mL; P < 0.05), whereas AUCs of 900 µg 25(OH)D3 were not significantly different between the 2 groups (P = 0.500).","A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],4427,188324,DB00146,Calcidiol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,84,239510,DB00146,Calcidiol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,111,239511,DB00146,Calcidiol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,33,239512,DB00146,Calcidiol
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,82,239513,DB00146,Calcidiol
,27569392,Tmax,The intervention markedly increased the blood 25(OH)D3 levels within the first five days (mean Tmax=5.1±2.1 d) and sustained an optimal circulating level of 25(OH)D3 (≥30 ng/mL) for 56 d.,Pharmacokinetics and effects of demographic factors on blood 25(OH)D3 levels after a single orally administered high dose of vitamin D3. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569392/),d,5.1,240846,DB00146,Calcidiol
